Novartis (NVS) Expected to Release Earnings on Tuesday

Key Points

• Novartis is expected to report Q3 2026 results before the market opens on October 27. Analysts forecast earnings of $2.25 per share and revenue of $14.56 billion, compared with $2.41 EPS and $14.95 billion in revenue in the prior reported quarter.
• Novartis shares recently traded at $150.16, down 0.3%, with a market capitalization of approximately $286.5 billion and a P/E ratio of 22.65.
• Analyst sentiment is mixed, with a consensus rating of “Hold” from 20 analysts and an average price target of $145.60; ratings include six Buys, 12 Holds and two Sells.

Novartis (NYSE:NVS - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to post earnings of $2.25 per share and revenue of $14.56 billion for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:00 AM ET.

Novartis (NYSE:NVS - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The company had revenue of $14.95 billion for the quarter. On average, analysts expect Novartis to post $8.91 EPS for the current fiscal year and $9.81 EPS for the next fiscal year.

Novartis Trading Down 0.3%

Shares of NYSE:NVS opened at $150.16 on Tuesday. Novartis has a 52-week low of $121.57 and a 52-week high of $170.46. The company has a market capitalization of $286.54 billion, a P/E ratio of 22.65, a price-to-earnings-growth ratio of 2.73 and a beta of 0.41. The company has a 50-day simple moving average of $148.21 and a 200 day simple moving average of $150.45. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. UBS Group reissued a "neutral" rating on shares of Novartis in a research report on Thursday, September 17th. Royal Bank Of Canada started coverage on Novartis in a research report on Tuesday, September 8th. They issued a "sector perform" rating for the company. Bank of America reaffirmed a "buy" rating on shares of Novartis in a research report on Tuesday, September 8th. Berenberg Bank reduced their target price on Novartis from $147.00 to $130.00 and set a "hold" rating for the company in a research note on Friday, September 11th. Finally, Weiss Ratings reissued a "buy (b)" rating on shares of Novartis in a report on Friday, July 24th. Six equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $145.60.

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company's research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.